Department of Gynecology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200030, China.
Department of Gynecology, The Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University, Luzhou, Sichuan, 646000, China.
BMC Cancer. 2024 Sep 2;24(1):1083. doi: 10.1186/s12885-024-12866-7.
Accumulating evidence has highlighted that lncRNA ABHD11-AS1 plays an essential role in tumorigenesis and is expected to become a new predictive biomarker and ideal target for cancer therapy, whereas some of their findings are conflicting due to the relatively small sample size of individual studies. Thus, this meta-analysis aimed to quantitatively ascertain the association of ABHD11-AS1 with diverse human malignancies.
Eight databases were comprehensively screened for relevant articles on January 1, 2024. The significance of ABHD11-AS1 in malignancies was determined by odds ratios (ORs) or hazard ratios (HRs) with corresponding 95% confidence interval (CI). Subgroup analyses and sensitivity analyses were applied to verify the reliability and robustness of the pooled results. Simultaneously, the GEPIA2021 and UCSC Xena databases were applied to further strengthen the results.
Fourteen clinical studies comprising eight kinds of malignancies and 1215 malignancy cases were enrolled into this meta-analysis. The pooled results showed that increased ABHD11-AS1 expression was remarkably associated with lymph node metastasis (OR = 2.73, 95%CI [1.97, 3.77], I = 0%, p < 0.00001), advanced tumor stage ( OR = 3.14, 95%CI [2.34, 4.21], I = 39%, p < 0.00001), and unfavorable overall survival (OS) (HR = 1.81, 95%CI [1.58, 2.06], I = 0%, p < 0.00001). Subgroup analyses and sensitivity analyses indicated that the pooled results were reliable and robust. Additionally, ABHD11-AS1 was significantly increased in eight kinds of malignancies according to the validation of the GEPIA2021 database. Meanwhile, the UCSC Xena databases further revealed that elevated ABHD11-AS1 expression was significantly associated with poor prognosis as assessed by progression free interval (PFI), disease free interval (DFI), disease specific survival (DSS), and OS.
Current evidence supports the association of elevated ABHD11-AS1 expression with poor prognosis. Thereby, ABHD11-AS1 may be considered as a promising biomarker to screen cancer and predict malignancy prognosis. Also, there is a necessity for larger-scale multicenter studies with uniform study protocols from different countries to further validate the conclusions.
越来越多的证据表明，lncRNA ABHD11-AS1 在肿瘤发生中起着重要作用，有望成为癌症治疗的新预测生物标志物和理想靶点，但由于个别研究的样本量相对较小，其部分研究结果存在冲突。因此，本荟萃分析旨在定量确定 ABHD11-AS1 与多种人类恶性肿瘤的相关性。
2024 年 1 月 1 日，全面检索了 8 个数据库中的相关文献。通过比值比（OR）或风险比（HR）及其相应的 95%置信区间（CI）确定 ABHD11-AS1 在恶性肿瘤中的意义。应用亚组分析和敏感性分析验证合并结果的可靠性和稳健性。同时，应用 GEPIA2021 和 UCSC Xena 数据库进一步加强结果。
本荟萃分析纳入了 14 项临床研究，涵盖了 8 种恶性肿瘤和 1215 例恶性肿瘤病例。合并结果表明，ABHD11-AS1 表达增加与淋巴结转移显著相关（OR=2.73，95%CI [1.97，3.77]，I=0%，p<0.00001），肿瘤分期较晚（OR=3.14，95%CI [2.34，4.21]，I=39%，p<0.00001）和不良的总生存（OS）（HR=1.81，95%CI [1.58，2.06]，I=0%，p<0.00001）。亚组分析和敏感性分析表明，合并结果可靠且稳健。此外，GEPIA2021 数据库的验证结果表明，ABHD11-AS1 在 8 种恶性肿瘤中显著增加。同时，UCSC Xena 数据库进一步表明，ABHD11-AS1 表达升高与无进展生存期（PFI）、无病生存期（DFI）、疾病特异性生存期（DSS）和 OS 等预后不良显著相关。
目前的证据支持 ABHD11-AS1 表达升高与不良预后相关。因此，ABHD11-AS1 可能被视为一种有前途的生物标志物，用于筛选癌症并预测恶性肿瘤的预后。此外，还需要来自不同国家的更大规模的多中心研究，采用统一的研究方案来进一步验证这些结论。
